-
Lipids: Protecting mRNA so it can protect our body
Underpinning the success of Covid-19 mRNA vaccines, lipid nanoparticles are set to transform the future of medicine by enabling the delivery of cutting-edge therapies into cells.
Learn More -
Acquisition of Exelead Completed
Today, the closing of the transaction to acquire Exelead, following regulatory clearances and the fulfillment of other customary closing conditions, for approximately USD 780 million in cash was announced.
Learn More -
First Vaccine Production Facility in Nigeria
Our Life Science business sector has signed an agreement with biotechnology company Innovative Biotech (IB) to design the manufacturing process for the first vaccine production facility in Nigeria.
Learn More -
Accelerates Scale Up of Lipids
To meet the high demand for lipids, a key component of mRNA-based vaccines and therapeutics, Merck KGaA, Darmstadt, Germany has launched a new, high-purity synthetic cholesterol product.
Learn More -
Merck KGaA, Darmstadt, Germany, and BioNTech Extend Strategic Partnership
Merck KGaA, Darmstadt, Germany, in close collaboration with BioNTech, will significantly accelerate the supply of urgently needed lipids and increase the amount of lipid delivery towards the end of 2021.
Learn More -
MilliporeSigma Expands Production Capacities
MilliporeSigma announced the broadening of its manufacturing footprint with a combined $47 million investment at its production facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire.
Learn More
Select your Market
-
{{ userContent.title }}
{{ userContent.lookingForMoreLabel }}
Our contributions to the fight against Covid-19
We are dedicated to serving patients, scientists, and healthcare providers around the world. With our products and expertise, we are contributing to the fight against Covid-19.
Our comprehensive commitment covers three main areas:
- Prevention & Production
- Diagnostics & Therapeutics
- Engagement & Collaboration
Facts & Figures
-
>80
Vaccine manufacturers are supported by us with products and services
-
>35
Covid-19 test systems use raw materials and services from our company
-
>50
Monoclonal antibodies, plasma products and antiviral drugs rely on us
-
Our contributions at a glance
In a nutshell: This summary contains an up-to-date overview about our commitment and initiatives in the fight against Covid-19.Detailed View
Prevention & Production
We are committed to providing researchers, developers and manufacturers with products and services needed for the Covid-19 response. To manage the unprecedented demand for Covid-19-related products, we have taken several proactive measures, e.g. comprehensive expansions of the production capacities at several of our sites.
Diagnostics & Therapeutics
Since the beginning of the pandemic, we have strongly invested in several key technologies that are crucial when it comes to vaccines, treatments and diagnostics applicable in Covid-19. Amongst others, this includes the expansion of our single-use assembly production capacities as well as significant steps in further broadening our expertise in the field of mRNA.
Working on Covid-19?
As a global life science supplier, we are here to help in the response to COVID-19. From supplying raw materials and research products for detection and characterization to production, we’ve consolidated relevant product and service offerings within a single page.
SIGMAALDRICH.COMEngagement & Collaboration
The issue of pandemic protection and preparedness has been important to us for several years already. Therefore, we have several initiatives in place to support the scientific community with funding and expertise – like our “Future Insight Prize” that awards top scientists for their outstanding research. And since the pandemic demands common efforts, we are also part of several international partnerships and collaborations addressing Covid-19.